1. Home
  2. LXU vs GYRE Comparison

LXU vs GYRE Comparison

Compare LXU & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LSB Industries Inc.

LXU

LSB Industries Inc.

HOLD

Current Price

$9.52

Market Cap

667.6M

Sector

Industrials

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$8.08

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXU
GYRE
Founded
1968
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
667.6M
755.7M
IPO Year
1969
N/A

Fundamental Metrics

Financial Performance
Metric
LXU
GYRE
Price
$9.52
$8.08
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$10.25
$17.00
AVG Volume (30 Days)
524.2K
77.0K
Earning Date
02-25-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.04
Revenue
$585,065,000.00
$107,265,000.00
Revenue This Year
$16.97
$11.59
Revenue Next Year
$0.90
$26.31
P/E Ratio
N/A
$201.83
Revenue Growth
12.49
2.13
52 Week Low
$4.88
$6.11
52 Week High
$10.17
$13.75

Technical Indicators

Market Signals
Indicator
LXU
GYRE
Relative Strength Index (RSI) 54.50 57.06
Support Level $9.23 $7.72
Resistance Level $10.17 $8.38
Average True Range (ATR) 0.37 0.33
MACD 0.02 0.06
Stochastic Oscillator 56.76 76.18

Price Performance

Historical Comparison
LXU
GYRE

About LXU LSB Industries Inc.

LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: